Negative pressure cabin for providing negative pressure for individuals

Abstract

The utility model discloses a negative pressure cabin for providing negative pressure for individuals, mainly relates to the field of medical facilities, in particular to a negative pressure cabin with an oxygen delivery device, and provides a negative pressure cabin which comprises a cabin body, a negative pressure device arranged on the cabin body and an oxygen delivery device arranged on or in the cabin body. Such a negative pressure compartment may be used for treating disease, resisting aging, promoting skin function, and / or beautifying for non-therapeutic purposes.

Description

[0001] Division Case Explanation

[0002] This application is a divisional application of the application with the application number "202322219036.6", the application date: August 17, 2023, and the utility model name "Negative Pressure Chamber for Providing Negative Pressure to Individuals". Technical Field

[0003] The present utility model relates to the field of medical facilities, and more particularly to a negative pressure chamber for providing negative pressure to individuals. Background Art

[0004] Cupping is a method of treating diseases in traditional Chinese medicine. Also known as cupping qi and suction cup therapy. Using a cup as a device, the air inside is exhausted by the heat of combustion to generate negative pressure, causing it to adhere to the skin, resulting in skin congestion at the cupped area. By creating a sterile inflammatory reaction in the body to stimulate the body's immune response, the purpose of treating diseases can be achieved. However, it is not suitable for use in cases such as high fever, convulsions, spasms, skin allergies or ulcerated and damaged areas, areas with thin muscles or uneven bones and prominent bones, and areas with a lot of hair.

[0005] A low-pressure and low-oxygen chamber is a device that can maintain the air pressure inside the chamber lower than the air pressure outside the chamber. It generally has good isolation properties and is usually used to isolate infectious patients, so that the viruses of infectious patients will not spread outside the chamber and prevent the re-spread of the virus. According to the Chinese national standard GB / T 35428—2017 "Environmental Control Requirements for Negative Pressure Isolation Wards in Hospitals", the negative pressure inside the negative pressure chamber relative to the outside air pressure generally does not exceed -20 Pa; for common negative pressure chamber products on the market, the negative pressure that can be generated relative to the outside air pressure generally does not exceed -100 Pa either. In addition, the low-pressure and low-oxygen environment (< -0.03 Mpa) in the low-pressure and low-oxygen chamber is also commonly used in the sports field. By enabling athletes to adapt to the low-oxygen environment inside the chamber, the oxygen-carrying capacity of red blood cells can be improved, thereby achieving the effect of improving sports performance. However, the low-pressure and low-oxygen environment in high-altitude areas is likely to cause altitude sickness in people due to hypoxia. Existing research on low-pressure and low-oxygen chambers has focused on the impact of the low-oxygen environment on the human body, and currently, no one has paid attention to reporting the impact of the negative pressure environment of the low-pressure and low-oxygen chamber on the body. Content of the Utility Model

[0006] In some embodiments, a negative pressure chamber for providing negative pressure to an individual is provided. In some embodiments, the negative pressure chamber includes a chamber body, a negative pressure device disposed on the chamber body, and an oxygen delivery device disposed on or inside the chamber body.

[0007] In some embodiments, the present utility model provides a negative pressure chamber for providing negative pressure to an individual, comprising: a chamber body sized to accommodate the whole body of the individual; a negative pressure device disposed on the chamber body such that the air pressure inside the chamber of the chamber body is lower than the air pressure outside the chamber; an oxygen supply device connected to the oxygen delivery device and in communication with the air pressure inside the chamber of the chamber body through the oxygen delivery device; and an oxygen delivery port connected to the oxygen delivery device.

[0008] In some embodiments, the oxygen supply device is configured to supply oxygen to the oxygen delivery device.

[0009] In some embodiments, the length of the chamber body is at least 1 meter.

[0010] In some embodiments, the length of the chamber body is from 1 to 2 meters.

[0011] In some embodiments, the length of the chamber body is from 1 to 1.5 meters.

[0012] In some embodiments, it further comprises a negative pressure breaking device disposed on the chamber body. In the first state of the negative pressure breaking device, the inside and the outside of the chamber are air pressure isolated, and in the second state of the negative pressure breaking device, the inside and the outside of the chamber are air pressure connected.

[0013] In some embodiments, it further comprises a perspective structure disposed on the chamber body to make the inside of the chamber visible relative to the outside, and / or make the outside of the chamber visible relative to the inside.

[0014] In some embodiments, at least a part of the oxygen delivery device is located inside the chamber.

[0015] In some embodiments, the oxygen delivery port is an oxygen mask and / or an oxygen inhalation tube.

[0016] In some embodiments, the negative pressure chamber further comprises: an oxygen supply device connected to the oxygen delivery device and in communication with the air pressure inside the chamber of the chamber body through the oxygen delivery device; and / or an oxygen delivery port connected to the oxygen delivery device for connecting to the individual to supply oxygen to the individual.

[0017] In some embodiments, the negative pressure chamber further comprises: a display device disposed on the chamber body; a lighting device disposed on the chamber body and facing the inside of the chamber; and / or a control device disposed on the chamber body for controlling at least one of the negative pressure device and the oxygen delivery device. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1A and Figure 1B shows a schematic diagram of a negative pressure chamber in some embodiments of the present disclosure.

[0019] Figure 1C and Figure 1D shows a schematic structural view of a negative pressure chamber in some embodiments of the present disclosure.

[0020] Figure 1A The reference numerals in Figures -1D are explained as follows: 1: perspective structure; 2: display device; 3: lighting device; 4: control device; 5: oxygen delivery device; 6: negative pressure device; 7: negative pressure breaking device; 8: hatch door; 10: chamber body; 11: inside the chamber; 12: outside the chamber.

[0021] Figure 2 is a comparison diagram of hair changes in senescent mice before and after 7 - day negative pressure treatment.

[0022] Figure 3A Figures -3D are comparison diagrams of changes in blood routine values of senescent mice before, during, and after negative pressure treatment, where Figure 3A is the white blood cell content (number of white blood cells per liter of blood), Figure 3B is the red blood cell content (number of red blood cells per liter of blood), Figure 3C is the platelet content (number of platelets per liter of blood), Figure 3D is the lymphocyte ratio.

[0023] Figure 4 shows the stratification of the lymphocyte layer and red blood cell layer of the blood of senescent mice before and after 7 - day negative pressure treatment.

[0024] Figure 5 is a microscopic view of a smear of the red blood cell layer of the blood of senescent mice before and after negative pressure treatment.

[0025] Figure 6 is the β - galactosidase staining of tissue sections of the liver, kidney, spleen, brain, and lung of senescent mice in the control group and the whole - body negative pressure -0.05 MPa treatment group.

[0026] Figure 7 is the hematoxylin - eosin staining of liver tissue sections of senescent mice in the control group and the whole - body negative pressure -0.05 MPa treatment group.

[0027] Figure 8 shows the hair growth conditions of mice in the control group, local negative pressure group, whole - body negative pressure -0.02 MPa treatment group, and whole - body negative pressure -0.05 MPa treatment group every day from day 0 to day 7 and on day 14.

[0028] Figure 9 shows the skin conditions of the local negative pressure group before and after local negative pressure.

[0029] Figure 10A–10D shows the comparison chart of blood routine values of mice in the control group, local negative pressure group, whole-body negative pressure -0.02 MPa treatment group, and whole-body negative pressure -0.05 MPa treatment group on the 14th day, where Figure 10A is the white blood cell content, Figure 10B is the red blood cell content, Figure 10C is the platelet content, Figure 10D is the lymphocyte ratio.

[0030] Figure 11 shows the oxygen proportion in the negative pressure cabin under different negative pressure values. Figure 11 A is the external view of the human negative pressure cabin and the subject model diagram; Figure 11 B is the blood oxygen concentration of the human body under different negative pressure values.

[0031] Figure 12 shows the results of negative pressure in clearing senescent cells, where Figure 12 A, 12B are the time-course changes of negative pressure in clearing β-Gal(+) BMSC, Figure 12 C, 12D are the time-course changes of apoptosis rates of young and senescent BMSC under negative pressure treatment.

[0032] Figure 13 shows the results of negative pressure treatment for osteoporosis in senescent mice, Figure 13 A, 13B, 13D are the changes of β-Gal(+) cells in peripheral blood monocytes of senescent mice after 6 weeks of negative pressure treatment; Figure 13 C, 13E are the changes of P16-positive cells in peripheral blood monocytes of senescent mice after 6 weeks of negative pressure treatment, Figure 13 F-13K are the MicroCT results and bone parameter changes of femoral bone restoration in senescent mice after 6 weeks of negative pressure treatment.

[0033] Figure 14 shows the change of life cycle of nematodes under negative pressure treatment.

[0034] Figure 15 shows the change of locomotor ability of nematodes under negative pressure treatment, where the arrow shows the position of the nematode.

[0035] Figure 16 shows the change of stored fat content of nematodes under different negative pressure treatments.

[0036] Figure 17 shows the change of survival rate of nematodes under different negative pressure treatments after acute heat stress.

[0037] Figure 18 shows the liver HE staining of negative pressure treatment for non-alcoholic fatty liver.

[0038] Figure 19 shows the liver oil red staining of negative pressure treatment for non-alcoholic fatty liver.

[0039] Figure 20 Shows the Sirius red staining of the liver in the treatment of non-alcoholic fatty liver by negative pressure.

[0040] Figure 21 Shows the NAS score in the treatment of non-alcoholic fatty liver by negative pressure.

[0041] Figure 22 Shows the plasma ALT content in the treatment of non-alcoholic fatty liver by negative pressure.

[0042] Figure 23 Shows the plasma and tissue cholesterol content in the treatment of non-alcoholic fatty liver by negative pressure.

[0043] Figure 24 Shows the bone restoration in the treatment of murine periodontitis by negative pressure.

[0044] Figure 25 Shows the blood routine of hyperuricemic mice after negative pressure treatment. Figure 25 A is the detection of the proportions of lymphocytes (LY), monocytes (MO), and neutrophils (GR), Figure 25 B is the detection of platelet-related indicators; Figure 25 C is the detection of red blood cell-related indicators.

[0045] Figure 26 Shows the change in body weight of hyperuricemic mice after negative pressure treatment, Figure 26 A is the schematic diagram of the animal experiment, Figure 26 B is the change in body weight of the mice.

[0046] Figure 27 Shows the comparison of the activities of hyperuricemic mice and mice after negative pressure treatment.

[0047] Figure 28 Shows the detection of indicators such as blood uric acid and serum creatinine in hyperuricemic mice after negative pressure treatment, Figure 28 A is the detection of blood uric acid, Figure 28 B is the detection of blood urea nitrogen (BUN), Figure 28 C is the detection of serum creatinine (CRE), Figure 28 D is the detection of xanthine oxidase (XOD) in liver tissue.

[0048] Figure 29 Shows the histological HE staining of the liver and kidney in hyperuricemic mice after negative pressure treatment.

[0049] Figure 30 Shows the Masson staining of kidney tissue in hyperuricemic mice after negative pressure treatment.

[0050] Figure 31Shows the immunofluorescence staining of renal tissue in hyperuricemia mice after negative pressure treatment.

[0051] Figure 32 Shows the change in the distance of LPR mice moving in the central area of the open field after negative pressure treatment.

[0052] Figure 33 Shows the changes in the movement time and the number of entries of LPR mice on the open arms of the elevated plus maze after negative pressure treatment.

[0053] Figure 34 Shows the changes in the movement time and the number of entries of LPR mice on the open arms of the elevated plus maze after negative pressure treatment compared with before their own treatment.

[0054] Figure 35 Shows the change in the immobile path of LPR mice in the forced swimming test after negative pressure treatment.

[0055] Figure 36 Shows the change in the immobile time of LPR mice in the forced swimming test after negative pressure treatment.

[0056] Figure 37 Shows the change in the colon length of mice with colonic inflammation model after negative pressure treatment.

[0057] Figure 38 Shows the change in the escape time of APP / PS1 mice in the Morris water maze after negative pressure treatment.

[0058] Figure 39 Shows the results of negative pressure treatment for atherosclerosis. Figure 39 A - 39C are respectively the results of oil red O staining of atherosclerotic plaques, triglyceride (TG) and total cholesterol (T - CHO) in ApoE - / - mice after negative pressure treatment. Detailed implementation manners

[0059] To further elaborate on the technical means and effects adopted by the present disclosure to achieve the predetermined purpose, the following, in combination with the accompanying drawings and preferred embodiments, details the specific implementation manners, structures, features and their effects according to the present disclosure.

[0060] It should be understood that the following disclosure provides many different embodiments for implementing different features of the present disclosure. The following describes specific embodiments or examples of the present disclosure to simplify the present disclosure. Of course, these are only examples and are not intended to be limiting. The sizes, shapes, proportions, and positions of the elements drawn in the drawings do not represent the true sizes, shapes, proportions, and positions in the embodiments of the present disclosure. The dimensions of the elements are not limited to the disclosed ranges or values, but may depend on manufacturing conditions, device characteristics, or actual requirements.

[0061] "Comprising" or "including" is intended to mean that a combination (such as a device, composition, or method, etc.) includes the recited elements (such as the units of a device, the components of a composition, or the substantial steps of a method, etc.), but does not exclude other elements. When used to define a composition and a method, "consisting essentially of" means excluding other elements that are of any significance for the purpose of the combination. Thus, a combination consisting essentially of the elements defined herein does not exclude other elements that do not substantially affect the basic and novel features of the claimed utility model. "Consisting of" means excluding other elements of the combination (unit components and substantial method steps). Embodiments defined by each of these transitional terms are within the scope of the present utility model.

[0062] In this document, "forming a first feature 'on' a second feature" may include embodiments where the first feature and the second feature are in direct contact, and may also include embodiments where additional features may be formed between the first feature and the second feature such that the first and second features may not be in direct contact. For simplicity and clarity, various features may be drawn arbitrarily in different scales. For example, the term "on the cabin" used in this disclosure does not merely mean that the mentioned element or component is located above the cabin or at a place away from the direction of gravity, but should be interpreted as the mentioned element or component being arranged adjacent to any side of the cabin or embedded in the cabin, where the mentioned element or component may be in direct contact with the cabin, or there may be additional elements therebetween without direct contact.

[0063] For ease of description, this disclosure uses spatial relative terms such as "below", "beneath", "under", "above", "over", "on", "in", "top", "bottom", "inside", "outside", "side", etc. to describe the relationship between one element or feature shown in the figures and another element or feature. In addition to the directions depicted in the figures, the spatial relative terms are intended to cover different directions during the use or operation of the device. The device may be oriented in other ways (rotated 90 degrees or other orientations), and the spatial relative descriptions used herein can be correspondingly interpreted. These spatial terms are only for the convenience of describing this disclosure and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and should not be construed as a limitation on this disclosure. In particular, the term "inside the cabin" used in this disclosure should be regarded as equivalent to "within the cabin", "inside the cabin", meaning the area, part, or space within the cabin; the term "outside the cabin" used in this disclosure should be regarded as equivalent to "outside the cabin", "beyond the cabin", meaning the area, part, or space outside the cabin, such as the atmosphere.

[0064] As used herein, the term "oxygen proportion (in a specified space)" means the proportion of oxygen in all the gases in the air within the specified space. For example, the oxygen proportion in the atmosphere is approximately 21% (by volume). Unless otherwise specified, the values of oxygen proportion mentioned herein shall be regarded as volume fractions, that is, the proportion of the volume of oxygen in the volume of all the gases in the air within the specified space.

[0065] In some embodiments, the cabin is divided into an interior and an exterior, particularly such that the interior and the exterior are only pneumatically connected through components on the cabin body. In some embodiments, in the first state, the interior and the exterior are pneumatically isolated, and in the second state, the interior and the exterior are pneumatically connected.

[0066] In some embodiments, the negative pressure device is used to provide negative pressure to an individual within the cabin. In some embodiments, the negative pressure is a systemic negative pressure. In some embodiments, the device is used to provide negative pressure to the whole body of an individual within the cabin where there is negative pressure.

[0067] In some embodiments, the individual is an animal, such as a vertebrate, and more particularly a mammal. In some embodiments, the individual is a human. In some embodiments, the individual is an adult. In some embodiments, the individual is a child. In some embodiments, the individual is a rat. In some embodiments, the individual is a mouse.

[0068] In some embodiments, the size of the cabin is such that it can accommodate the whole body of an individual within the cabin. In some embodiments, the length of the cabin is at least 1 meter, particularly 1 to 2 meters, and more particularly 1 to 1.5 meters. In some embodiments, the width of the cabin is at least 1 meter, particularly 1 to 2 meters, and more particularly 1 to 1.5 meters. In some embodiments, the height of the cabin is at least 2 meters, particularly 2 to 3 meters, and more particularly 2 to 2.5 meters. In some embodiments, the volume of the cabin is at least 1 cubic meter, particularly at least 2 cubic meters, and more particularly 2 to 3 cubic meters.

[0069] In some embodiments, the negative pressure device is capable of making the air pressure inside the cabin of the cabin body lower than the air pressure outside the cabin of the cabin body. In some embodiments, the negative pressure device is capable of making the air pressure inside the cabin of the cabin body lower than the air pressure outside the cabin of the cabin body by at least 0.01 MPa, particularly at least 0.02 MPa, particularly at least 0.03 MPa, particularly at least 0.04 MPa. In some embodiments, the negative pressure device is capable of making the air pressure inside the cabin of the cabin body lower than the air pressure outside the cabin of the cabin body by 0.04 - 0.06 MPa, particularly 0.045 - 0.055 MPa, particularly 0.05 MPa. In some embodiments, the negative pressure device is located on the wall of the cabin body. For example, it is located on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the negative pressure device is located on the side wall of the cabin body. In some embodiments, the negative pressure device is located on the ceiling of the cabin body. In some embodiments, the negative pressure device is located on the floor of the cabin body. In some embodiments, the negative pressure device includes a vacuum pump. In some embodiments, the negative pressure device is connected to a vacuum pump.

[0070] In some embodiments, the oxygen delivery device is configured to make the proportion of oxygen in the air in the space of the respiratory systems of adjacent individuals in the chamber greater than the proportion of oxygen in the air outside the chamber (i.e., the atmosphere). In some embodiments, the oxygen delivery device is configured to make the proportion of oxygen in the space of the respiratory systems of adjacent individuals in the chamber greater than or equal to the proportion of oxygen outside the chamber, particularly at least 22%, particularly at least 23%, particularly at least 24%, particularly at least 25%, particularly at least 30%, particularly at least 35%, particularly at least 40%, particularly at least 50%. In some embodiments, the oxygen delivery device is configured to deliver oxygen with an oxygen partial pressure greater than or equal to the oxygen partial pressure in the chamber to an individual in the chamber. In some embodiments, the oxygen delivery device is configured to deliver oxygen to an individual in the chamber that is at least 1.2 times, particularly at least 1.5 times, more particularly at least 2 times, the oxygen partial pressure in the chamber. In some embodiments, the oxygen delivery device is configured to deliver a gas with an oxygen proportion greater than or equal to the oxygen proportion in the atmosphere to an individual in the chamber, particularly to provide a gas with an oxygen proportion exceeding 50%, particularly to provide a gas with an oxygen proportion exceeding 75%, particularly to provide a gas with an oxygen proportion exceeding 95%. In some embodiments, the oxygen delivery device is configured to deliver oxygen with an oxygen partial pressure greater than or equal to the oxygen partial pressure outside the chamber of the chamber body to an individual in the chamber. In some embodiments, the oxygen delivery device delivers gas to the chamber in a first state and does not deliver gas to the chamber in a second state. In some embodiments, the oxygen delivery device delivers oxygen to the chamber in a first state and does not deliver oxygen to the chamber in a second state. In some embodiments, at least a portion of the oxygen delivery device is located inside the chamber. In some embodiments, the oxygen delivery device is located on the wall of the chamber body. For example, it is located on the ceiling, floor, and / or side wall of the chamber body. In some embodiments, the oxygen delivery device is located on the side wall of the chamber body. In some embodiments, the oxygen delivery device is located on the ceiling of the chamber body. In some embodiments, the oxygen delivery device is located on the floor of the chamber body. In some embodiments, the oxygen delivery device is located inside the chamber. In some embodiments, the negative pressure chamber further includes an oxygen supply device. In some embodiments, the oxygen supply device is connected to the oxygen delivery device and is in communication with the air pressure in the chamber through the oxygen delivery device. In some embodiments, the oxygen supply device is configured to provide oxygen to the chamber. In some embodiments, the oxygen supply device is a high-pressure oxygen cylinder and / or an oxygen generator, particularly a high-pressure oxygen cylinder. In some embodiments, the negative pressure chamber further includes an oxygen delivery port. In some embodiments, the oxygen delivery port is connected to the oxygen delivery device to provide oxygen to an individual. In some embodiments, the oxygen delivery port is, for example, an oxygen mask and / or an oxygen inhalation tube, particularly an oxygen mask.

[0071] In some embodiments, the oxygen delivery device is connected to the oxygen delivery port. In some embodiments, the oxygen delivery device is connected to the oxygen supply device. In some embodiments, the oxygen delivery device includes an oxygen vent pipe or an oxygen vent. In some embodiments, the oxygen delivery device includes an oxygen vent pipe or an oxygen vent, wherein the oxygen vent pipe or the oxygen vent is connected to the oxygen delivery port and the oxygen supply device.

[0072] In some embodiments, the negative pressure chamber further includes a negative pressure breaking device located on the chamber body. In some embodiments, the negative pressure breaking device can make the air pressure inside the chamber of the chamber body communicate with the air pressure outside the chamber. In some embodiments, the negative pressure breaking device is such that in the first state, the air pressure inside the chamber of the chamber body communicates with the air pressure outside the chamber, and in the second state, the air pressure inside the chamber of the chamber body is isolated from the air pressure outside the chamber. In some embodiments, the negative pressure breaking device can make the air pressure inside the chamber of the chamber body tend to be equal to or almost equal to the air pressure outside the chamber of the chamber body. In some embodiments, the negative pressure breaking device includes a valve. In some embodiments, the negative pressure breaking device is arranged such that when there is a pressure difference between the inside and outside of the chamber, for example, when the air pressure inside the chamber is lower than the air pressure outside the chamber of the chamber body, the inside and outside of the chamber change from air pressure isolation to air pressure communication. In some embodiments, the negative pressure breaking device is located on the wall of the chamber body. For example, it is located on the ceiling, floor, and / or side wall of the chamber body. In some embodiments, the negative pressure breaking device is located on the side wall of the chamber body. In some embodiments, the negative pressure breaking device is located on the ceiling of the chamber body. In some embodiments, the negative pressure breaking device is located on the floor of the chamber body.

[0073] In some embodiments, the negative pressure chamber further includes a hatch. In some embodiments, the hatch is located on the wall of the chamber body. For example, it is located on the ceiling, floor, and / or side wall of the chamber body. In some embodiments, the hatch is located on the side wall of the chamber body. In some embodiments, the hatch is located on the ceiling of the chamber body. In some embodiments, the hatch is located on the floor of the chamber body. In some embodiments, the hatch is arranged such that in the first state, the air pressure inside the chamber of the chamber body communicates with the air pressure outside the chamber, and in the second state, the air pressure inside the chamber of the chamber body is isolated from the air pressure outside the chamber. In some embodiments, the height of the hatch is at least 0.9 meters, particularly 0.9 to 1.35 meters, particularly 0.9 to 1.2 meters. In some embodiments, the height of the hatch is at least 1.8 meters, particularly 1.8 to 2.7 meters, particularly 1.8 to 2.4 meters.

[0074] In some embodiments, the negative pressure chamber further includes a perspective structure. In some embodiments, the perspective structure is located on the wall of the chamber. For example, it is located on the ceiling, floor, and / or side wall of the chamber. In some embodiments, the perspective structure is located on the side wall of the chamber. In some embodiments, the perspective structure is located on the ceiling of the chamber. In some embodiments, the perspective structure is located on the floor of the chamber. In some embodiments, the perspective structure includes a transparent material. In some embodiments, the perspective structure enables the interior of the chamber to be visible relative to the exterior. In some embodiments, the perspective structure enables the exterior of the chamber to be visible relative to the interior. In some embodiments, the perspective structure is a window. In some embodiments, the perspective structure is a fixed window.

[0075] In some embodiments, the negative pressure chamber further includes a display device. In some embodiments, the display device is located on the wall of the chamber. For example, it is located on the ceiling, floor, and / or side wall of the chamber. In some embodiments, the display device is located on the side wall of the chamber. In some embodiments, the display device is located on the ceiling of the chamber. In some embodiments, the display device is located on the floor of the chamber. In some embodiments, the display device faces the interior of the chamber. In some embodiments, the display device faces the exterior of the chamber. In some embodiments, the negative pressure chamber includes a plurality of display devices. One of the plurality of display devices faces the exterior, and one of the plurality of display devices faces the interior. In some embodiments, the display device is a display screen. In some implementation devices, the display device is an interactive device, such as a touch display screen.

[0076] In some embodiments, the negative pressure chamber further includes a lighting device. In some embodiments, the lighting device is located on the wall of the chamber. For example, it is located on the ceiling, floor, and / or side wall of the chamber. In some embodiments, the lighting device is located on the side wall of the chamber. In some embodiments, the lighting device is located on the ceiling of the chamber. In some embodiments, the lighting device is located on the floor of the chamber. In some embodiments, the lighting device faces the interior of the chamber. In some embodiments, the lighting device faces the exterior of the chamber. In some embodiments, the negative pressure chamber includes a plurality of lighting devices, one of the plurality of lighting devices faces the exterior, and one of the plurality of lighting devices faces the interior.

[0077] In some embodiments, the negative pressure chamber further includes a control device. In some embodiments, the control device is located on the wall of the chamber. For example, it is located on the ceiling, floor, and / or side wall of the chamber. In some embodiments, the control device is located on the side wall of the chamber. In some embodiments, the control device is located on the ceiling of the chamber. In some embodiments, the control device is located on the floor of the chamber. In some embodiments, the control device controls at least one selected from the group consisting of a perspective structure, a display device, a lighting device, an oxygen delivery device, an oxygen supply device, an oxygen delivery port, a negative pressure device, a vacuum pump, a negative pressure breaking device, and a hatch. In some embodiments, the control device controls the perspective structure. In some embodiments, the perspective device controls the display device. In some embodiments, the perspective device controls the lighting device. In some embodiments, the perspective device controls the oxygen delivery device. In some embodiments, the perspective device controls the oxygen supply device. In some embodiments, the perspective device controls the oxygen delivery port. In some embodiments, the perspective device controls the negative pressure device. In some embodiments, the perspective device controls the vacuum pump. In some embodiments, the perspective device controls the negative pressure breaking device. In some embodiments, the perspective device controls the hatch.

[0078] In some embodiments, the diseases include those selected from the group consisting of or consisting of skin, liver, spleen, brain, kidney, and red blood cell-related diseases. In some embodiments, the diseases include those selected from the group consisting of or consisting of liver, spleen, brain, and kidney-related diseases. In some embodiments, the disease is a skin-related disease. In some embodiments, the disease is a liver-related disease. In some embodiments, the disease is a spleen-related disease. In some embodiments, the disease is a brain-related disease. In some embodiments, the disease is a kidney-related disease. In some embodiments, it is a red blood cell-related disease.

[0079] In some embodiments, anti-aging includes reducing the number of senescent cells in a tissue or an organ. In some embodiments, the tissue or the organ includes at least one selected from the group consisting of skin, liver, spleen, brain, kidney, and red blood cells, or consists of the same. In some embodiments, the tissue or the organ includes at least one selected from the group consisting of liver, spleen, brain, and kidney, or consists of the same. In some embodiments, the tissue or the organ includes skin or consists of the same. In some embodiments, the tissue or the organ includes liver or consists of the same. In some embodiments, the tissue or the organ includes spleen or consists of the same. In some embodiments, the tissue or the organ includes brain or consists of the same. In some embodiments, the tissue or the organ includes kidney or consists of the same. In some embodiments, the tissue or the organ includes red blood cells or consists of the same. In some embodiments, anti-aging includes reducing the number of senescent skin cells or reducing the proportion of senescent skin cells among skin cells. In some embodiments, anti-aging includes reducing the number of senescent liver cells or reducing the proportion of senescent liver cells among liver cells. In some embodiments, anti-aging includes reducing the number of senescent spleen cells or reducing the proportion of senescent spleen cells among spleen cells. In some embodiments, anti-aging includes reducing the number of senescent brain cells or reducing the proportion of senescent brain cells among brain cells. In some embodiments, anti-aging includes reducing the number of senescent kidney cells or reducing the proportion of senescent kidney cells among kidney cells. In some embodiments, anti-aging includes reducing the number of senescent red blood cells or reducing the proportion of senescent red blood cells among red blood cells.

[0080] In some embodiments, the whole-body negative pressure is a negative pressure of at least 0.01 MPa relative to the atmospheric pressure. In some embodiments, the whole-body negative pressure is a negative pressure of at least 0.02 MPa relative to the atmospheric pressure. In some embodiments, the whole-body negative pressure is a negative pressure of at least 0.03 MPa relative to the atmospheric pressure. In some embodiments, the whole-body negative pressure is a negative pressure of at least 0.04 MPa relative to the atmospheric pressure. In some embodiments, the whole-body negative pressure is a negative pressure of 0.04 MPa to 0.06 MPa relative to the atmospheric pressure. In some embodiments, the whole-body negative pressure is a negative pressure of 0.045 MPa to 0.055 MPa relative to the atmospheric pressure. In some embodiments, the whole-body negative pressure is a negative pressure of 0.05 MPa relative to the atmospheric pressure.

[0081] In some embodiments, applying whole-body negative pressure to an individual is implemented by a device for applying whole-body negative pressure to the individual. In some embodiments, the device for applying whole-body negative pressure to the individual has a length of at least 1 meter, particularly 1 to 2 meters, especially 1 to 1.5 meters. In some embodiments, the device for applying whole-body negative pressure to the individual has a width of at least 1 meter, particularly 1 to 2 meters, especially 1 to 1.5 meters. In some embodiments, the device for applying whole-body negative pressure to the individual has a height of at least 2 meters, particularly 2 to 3 meters, especially 2 to 2.5 meters. In some embodiments, the device for applying whole-body negative pressure to the individual has a volume of at least 1 cubic meter, particularly at least 2 cubic meters, especially 2 to 3 cubic meters.

[0082] In some embodiments, the proportion of oxygen in the air under whole-body negative pressure is greater than or equal to the proportion of oxygen in the atmosphere. In some embodiments, the proportion of oxygen in the air under whole-body negative pressure is greater than the proportion of oxygen in the atmosphere. In some embodiments, the proportion of oxygen in the air under whole-body negative pressure is at least 22%, particularly at least 23%, especially at least 24%, particularly at least 25%, especially at least 30%, particularly at least 35%, especially at least 40%, particularly at least 50%.

[0083] In some embodiments, applying whole-body negative pressure to an individual is carried out while simultaneously supplying air with an oxygen proportion greater than or equal to the proportion of oxygen in the atmosphere to the respiratory system of the individual. In some embodiments, the device for applying whole-body negative pressure to the individual also simultaneously supplies air with an oxygen proportion greater than or equal to the proportion of oxygen in the atmosphere to the respiratory system of the individual. In some embodiments, the methods for treating diseases, anti-aging, promoting skin function, and / or non-therapeutic beauty purposes for an individual also include supplying air with an oxygen proportion greater than or equal to the proportion of oxygen in the atmosphere to the respiratory system of the individual.

[0084] In some embodiments, the oxygen proportion of the air supplied to the respiratory system of the individual is greater than the proportion of oxygen in the atmosphere by at least 22%, particularly at least 23%, especially at least 24%, particularly at least 25%, especially at least 30%, particularly at least 35%, especially at least 40%, particularly at least 50%.

[0085] Through the exploration of mechanisms and the confirmation of experiments, the applicant found that the systematic mechanism changes brought about by whole-body negative pressure are not possessed by local negative pressure. This may be because, for example, the impacts of the two on the body's circulatory system are significantly different, such as Figure 4 and Figure 10A shown in Fig. –10D. This may be closely related to the obvious differences in the effects of the two in ultimately promoting the improvement of the functions of skin-related structures.

[0086] In the description and drawings of the present application, especially in the following embodiments, unless otherwise clearly stated, the air pressure difference expressed in MPa is obtained by subtracting the air pressure outside the negative pressure chamber from the air pressure inside the negative pressure chamber. For example, the air pressure difference of "-0.05 MPa" means that the air pressure inside the chamber is 0.05 MPa lower than the air pressure outside the chamber.

[0087] In the description and drawings of the present application, the term "Day 0" means before the negative pressure treatment, and the term "Day n " ( n = 1–14) is counted starting from the first day of the negative pressure treatment as Day 1. If there is a negative pressure treatment on the same day, it is after the negative pressure treatment. For example, "Day 7" is after 7 days of negative pressure treatment starting from Day 1, and "Day 14" is the 7th day after 7 days of negative pressure treatment starting from Day 1 and then restoring to the normal breeding environment (without negative pressure treatment).

[0088] In this article, unless otherwise specified, the oxygen content in Examples 3 - 15 is 20 kPa---21 kPa.

[0089] In this article, unless otherwise specified, "local negative pressure" means performing a negative pressure treatment of -0.02 MPa locally for 10 minutes per day for 7 days.

[0090] In the embodiments of this article, unless otherwise specified, the negative pressure treatment of the test animals is as follows:

[0091] After moving the test animals into the interior of the chamber, close the chamber door tightly and perform the negative pressure treatment. The air pressure for the negative pressure treatment is -0.04 MPa to -0.06 MPa. After the negative pressure treatment is completed, open the chamber door, move the test animals out, and then perform ultraviolet disinfection treatment. Perform the negative pressure treatment for 2 hours per day for 7 days.

[0092] In some embodiments, the negative pressure chamber is used for adults; in some embodiments, the negative pressure chamber is used for non-pregnant individuals.

[0093] Example 1 Negative Pressure Chamber

[0094] Figure 1A and Figure 1B show a schematic diagram of a negative pressure chamber in some embodiments of the present disclosure. Figure 1C and Figure 1D show a schematic structural diagram of a negative pressure chamber in some embodiments of the present disclosure.

[0095] The negative pressure chamber can apply whole-body negative pressure to an individual. In some embodiments, the negative pressure chamber 100 includes a chamber body 10. The chamber body 10 divides the space into an interior 11 of the chamber and an exterior 12 of the chamber.

[0096] The negative pressure chamber 100 may include a negative pressure device 6 on the chamber body 10. The negative pressure device 6 may be located on any wall of the chamber body 10, for example, on the ceiling, floor, and / or side wall of the chamber body 10. The negative pressure device 6 can be used to create a pressure difference between the inside 11 and the outside 12 of the chamber, for example, to make the pressure inside 11 less than that outside 12, and / or to make the pressure inside 11 less than the atmospheric pressure. In some embodiments, the negative pressure device 6 may be connected to a vacuum pump 61 for pumping out the gas inside 11 of the chamber.

[0097] The negative pressure chamber 100 may include a negative pressure breaking device 7 on the chamber body 10. The negative pressure breaking device 7 may be located on any wall of the chamber body 10, for example, on the ceiling, floor, and / or side wall of the chamber body 10. The negative pressure breaking device 7 can reduce the pressure difference between the inside 11 and the outside 12 of the chamber, for example, to make the inside 11 and the outside 12 of the chamber communicate in terms of air pressure, so that the pressure difference between the inside 11 and the outside 12 drops to zero or close to zero, or in other words, the air pressures inside 11 and outside 12 are equal or almost equal. In some embodiments, the negative pressure breaking device 7 may be a valve. By opening the valve, the inside 11 and the outside 12 of the chamber can communicate in terms of air pressure, reducing the pressure difference between the inside 11 and the outside 12, for example, to make the pressure difference between the inside 11 and the outside 12 drop to zero or close to zero, or in other words, the air pressures inside 11 and outside 12 are equal or almost equal; while when the valve is closed, the inside 11 and the outside 12 of the chamber are isolated in terms of air pressure. In some embodiments, the negative pressure device 6 and the negative pressure breaking device 7 may be the same structure. In some embodiments, the negative pressure device 6 and the negative pressure breaking device 7 may be two separate structures.

[0098] The negative pressure chamber 100 may include an oxygen supply device 5 on the chamber body 10 or inside 11 of the chamber. In some embodiments, at least a part of the oxygen supply device 5 is located inside 11 of the chamber. Specifically, in some embodiments, the oxygen supply device 5 may be located on any wall of the chamber body 10, for example, on the ceiling, floor, and / or side wall of the chamber body 10; in some embodiments, the oxygen supply device 5 is completely located inside 11 of the chamber. The oxygen supply device 5 can be used to increase the oxygen partial pressure at a specific part inside 11 of the chamber, for example, to make the proportion of oxygen in the air at a specific part inside 11 higher than that outside 12 or at other parts inside 11 of the chamber, and more specifically, to make the oxygen partial pressure at a specific part inside 11 equal to the oxygen partial pressure outside 12. In some embodiments, the oxygen supply device 5 may be connected to an oxygen supply device 51, and the oxygen supply device 51 is used to supply oxygen to the oxygen supply device so that the oxygen supply device 5 can deliver oxygen to the inside 11 of the chamber.

[0099] In some embodiments, the oxygen delivery device 5 can be connected to an oxygen delivery port 52, such as an oxygen mask, for connecting to an individual inside the cabin 11, such as connecting to their respiratory tract, to deliver oxygen to them, such as making the proportion of oxygen in the air adjacent to a part of the individual higher than that in the air outside the cabin 12 or other parts of the air inside the cabin 11, and more specifically making the partial pressure of oxygen in the air adjacent to a part of the individual equal to the partial pressure of oxygen outside the cabin 12.

[0100] In some embodiments, the negative pressure cabin 100 can be on the cabin body 10 and can include a cabin door 8. The cabin door 8 can be located on any one of the walls of the cabin body 10, such as on the ceiling, floor, and / or side walls of the cabin body 10. The cabin door 8 can be used to allow an individual to enter and exit the cabin body 10. In some embodiments, the cabin door 8 can be an airtight cabin door. In some embodiments, when the cabin door 8 is opened, the air pressure inside the cabin 11 is in communication with the air pressure outside the cabin 12. In some embodiments, when the cabin door 8 is closed, the air pressure inside the cabin 11 is isolated from the air pressure outside the cabin 12, that is, there can be a pressure difference between the air pressure inside the cabin 11 and the air pressure outside the cabin 12, or it can be said that the air pressure inside the cabin 11 is isolated from the atmosphere.

[0101] There are no particular restrictions on the materials and structures of the cabin body 10 and / or the cabin door 8, as long as they can withstand the air pressure difference between the air pressure inside the cabin 11 and the air pressure outside the cabin 12 created by the negative pressure device 6. There are also no restrictions on the sizes of the cabin body 10 and / or the cabin door 8, as long as they can accommodate the whole body of the individual to whom negative pressure is to be applied. For example, in some embodiments, if the cabin body 10 is used to apply negative pressure to a human, its size can be set to be able to accommodate the whole body of a human, for example, with a length of more than 1 meter, a width of more than 1 meter, and / or a height of more than 2 meters, such as a length of more than 1.5 meters, a width of more than 1.5 meters, and / or a height of more than 2.5 meters, and / or a volume of more than 1 cubic meter, but not limited thereto; if the cabin door 8 is used to allow a human to enter and exit the cabin body 10, its size can be set to a size that allows a human to pass through, such as a width of more than 0.9 meters and / or a height of more than 1.8 meters, but not limited thereto.

[0102] In some embodiments, the negative pressure cabin 100 on the cabin body 10 can include a perspective structure 1. In some embodiments, the perspective structure 1 can be located on any one of the walls of the cabin body 10, such as on the ceiling, floor, and / or side walls of the cabin body 10, especially on the side walls. In some embodiments, the perspective structure 1 can include a transparent material, such as glass or transparent plastic, so that an observer outside the cabin 12 can observe the situation inside the cabin 11, and / or an observer inside the cabin 11 can observe the situation outside the cabin 12. In some embodiments, the perspective structure 1 can be a window, such as a fixed window.

[0103] In some embodiments, the negative pressure chamber 100 may include a display device 2 on the chamber body 10. In some embodiments, the display device 2 may be located on any wall of the chamber body 10, such as on the ceiling, floor, and / or side wall of the chamber body 10, particularly on the side wall. In some embodiments, the display device 2 may be a display screen. In some embodiments, the display device 2 may have an interactive function, for example, the display device 2 may be a touch display screen. In some embodiments, the display device 2 may face outward 12 of the chamber. In some embodiments, the display device 2 may face inward 11 of the chamber. In some embodiments, the display device 2 may face both outward 12 and inward 11 of the chamber simultaneously. In some embodiments, multiple display devices 2 may be included, one or more of which face outward 12 of the chamber, and the other or others of which face inward 11 of the chamber.

[0104] In some embodiments, the negative pressure chamber 100 may include a lighting device 3 on the chamber body 10 for providing lighting inside the chamber 11. In some embodiments, the lighting device 3 may be arranged below the ceiling of the chamber body 10 and face inward 11 of the chamber.

[0105] In some embodiments, the negative pressure chamber 100 may include a control device 4 on the chamber body 10 for controlling one or more of, for example, the perspective structure 1, the display device 2, the lighting device 3, the oxygen supply device 5, the negative pressure device 6, and the negative pressure breaking device 7. In some embodiments, the control device 4 may be located on any wall of the chamber body 10, such as on the ceiling, floor, and / or side wall of the chamber body 10, particularly on the side wall. In some embodiments, the control device 4 may be a power switch for controlling the opening or closing of one or more of, for example, the display device 2, the lighting device 3, the oxygen supply device 5, the negative pressure device 6, and the negative pressure breaking device 7. In some embodiments, the control device 4 may be a control device for controlling the lighting device 3, for example, the switch of the lighting device 3. In some embodiments, the control device 4 may be a control device for controlling the display device 2. In some embodiments, the control device 4 may be a control device for controlling the oxygen supply device 5. In some embodiments, the control device 4 may be a control device for controlling the negative pressure device 6. In some embodiments, the control device 4 may be a control device for controlling the negative pressure breaking device 7, for example, the switch of the negative pressure breaking device 7. In some embodiments, the control device 4 may be a control device for controlling the chamber door 8, for example, the switch of the chamber door 8. In some embodiments, the control device 4 may be a control device for controlling the perspective structure 1. In some embodiments, multiple control devices 4 may be included for controlling different elements among multiple ones of the perspective structure 1, the display device 2, the lighting device 3, the oxygen supply device 5, the negative pressure device 6, the negative pressure breaking device 7, and the chamber door 8.

[0106] Example 2 Method of Using the Negative Pressure Chamber

[0107] In some embodiments, the method of using the negative pressure chamber 100 is as described below.

[0108] Have an individual enter the chamber 11. For example, have the individual enter the chamber 11 by themselves, or move the individual into the chamber 11. In some embodiments, the individual can be a human, or other animals such as rats or mice. The age and body size of the individual are not particularly limited in the present disclosure, as long as the individual can enter the chamber 11 as a whole, or the chamber 10 can accommodate the whole body of the individual.

[0109] Connect the oxygen delivery device 5 to the individual. In some embodiments, the oxygen mask in the oxygen delivery device 5 is connected to the respiratory system of the individual, for example, by having the individual wear the oxygen mask. In some embodiments, the oxygen delivery device 5 can be connected to the individual before the individual enters the chamber 11. In some embodiments, the oxygen delivery device 5 can be connected to the individual after the individual enters the chamber 11.

[0110] After the individual enters the chamber 11, close the chamber door 8 so that the air pressure in the chamber 11 is isolated from the air pressure outside the chamber 12, that is, the chamber 11 is isolated from the atmosphere. In some embodiments, the chamber door 8 can be closed before the oxygen delivery device 5 is connected to the individual. In some embodiments, the chamber door 8 can be closed after the oxygen delivery device 5 is connected to the individual.

[0111] Use the negative pressure device 6 to reduce the air pressure in the chamber 11, creating a certain air pressure difference between the chamber 11 and the outside of the chamber 12, and maintaining the air pressure difference between the chamber 11 and the outside of the chamber 12 so that the individual is in an environment with a lower air pressure than the air pressure outside the chamber 12. In some embodiments, oxygen can be provided to the individual through the oxygen delivery device 5. In some embodiments, the whole body of the individual is in an environment with a lower air pressure than the air pressure outside the chamber 12.

[0112] Use the negative pressure breaking device 7 to connect the air pressure in the chamber 11 with the air pressure outside the chamber 12, reducing the air pressure difference between the chamber 11 and the outside of the chamber 12. For example, the air pressure difference between the chamber 11 and the outside of the chamber 12 is reduced to zero or close to zero, or the air pressure in the chamber 11 and the outside of the chamber 12 is equal or almost equal.

[0113] Have the individual leave the chamber 11. In some embodiments, after the individual leaves the chamber 11, subsequent processing can be performed, such as ultraviolet disinfection treatment.

[0114] Example 3 Comparison of senescent mice before and after negative pressure treatment

[0115] 1. Experimental method

[0116] 1-year-old senescent C57BL6 mice were used as the test animals. The experimental groups included a control group (without negative pressure treatment) and a whole-body negative pressure -0.05 MPa treatment group (using the negative pressure chamber disclosed in the present disclosure, with the whole-body negative pressure of -0.05 MPa applied for 2 hours per day for 7 days).

[0117] On the 0th day and the 7th day, the test animals in the whole-body negative pressure -0.05 MPa treatment group (using the negative pressure chamber disclosed in the present disclosure, with the whole-body negative pressure of -0.05 MPa applied for 2 hours per day for 7 days) were anesthetized with isoflurane, photographed, and the hair changes before and after negative pressure were compared.

[0118] On the 0th day, 1st day, 3rd day, and 7th day, the test animals in the whole-body negative pressure -0.05 MPa treatment group were anesthetized and blood was collected for routine blood tests. The lymphocyte layer and red blood cell layer of the senescent mice were separated using mouse lymphocyte separation solution, and the red blood cells were then smeared for observation.

[0119] For the test animals in the control group and the whole-body negative pressure -0.05 MPa treatment group on the 7th day, after blood collection, they were sacrificed by cervical dislocation, and then various tissue organs such as the heart, liver, spleen, lungs, kidneys, and brain were separated. After fixation with paraformaldehyde, dehydration, paraffin embedding and other treatments were carried out, tissue sections with a thickness of 5 µm were cut, and senescent cells were stained and observed using β-galactosidase staining, and hematoxylin-eosin staining (commonly known as HE staining) was performed on important organs for observation.

[0120] 2. Experimental results

[0121] (1) Hair changes in senescent mice before and after negative pressure

[0122] Figure 2 It is a comparison chart of hair changes in senescent mice before and after 7 days of negative pressure treatment.

[0123] As Figure 2 shown, before 7 days of negative pressure treatment (the 0th day) of the senescent mice, a few white hairs could be seen mixed in the hair, and there were partial hair loss and wounds in the center of the back. After 7 days of negative pressure treatment (the 7th day) of the senescent mice, the hair was thick and the number of white hairs decreased, the wound in the center of the back healed, and new hair grew back.

[0124] (2) Effect of negative pressure on routine blood tests in senescent mice

[0125] Figure 3A –3D is a comparison chart of the changes in routine blood test values in senescent mice before, during, and after negative pressure treatment (the 0th day, 1st day, 3rd day, 7th day), where Figure 3A is the white blood cell content, Figure 3B is the red blood cell content, Figure 3C is the platelet content, Figure 3Dis the proportion of lymphocytes.

[0126] As Figure 3A –3D shows, after the negative pressure treatment of senescent mice, the white blood cells decreased, the proportion of lymphocytes in the total number of white blood cells increased, the red blood cells increased after 7 days of negative pressure treatment, and the platelets increased.

[0127] (3)Effect of negative pressure on lymphocyte layer and red blood cell layer in senescent mice

[0128] Figure 4 shows the stratification of blood lymphocyte layer and red blood cell layer of the blood of senescent mice before and after negative pressure treatment; while Figure 5 is the microscopic picture of the smear observation of the blood red blood cell layer of senescent mice before and after negative pressure treatment.

[0129] As Figure 4 shows, after 7 days of negative pressure treatment of senescent mice, the lymphocyte stratification is more obvious, the number increases, and the red blood cell layer increases. As Figure 5 shows, after 1 day of negative pressure treatment of senescent mice, the number of senescent red blood cells increases, and the number of senescent red blood cells decreases after 3 days and 7 days of negative pressure treatment.

[0130] (4)Changes of senescent cells in various tissues and organs of senescent mice before and after negative pressure

[0131] Figure 6 is the β-galactosidase staining of tissue sections of liver, kidney, spleen, brain and lung of senescent mice in the control group and the whole body negative pressure -0.05 MPa treatment group. Figure 7 is the hematoxylin-eosin staining of tissue sections of liver, kidney, spleen, brain and lung of senescent mice in the control group and the whole body negative pressure -0.05 MPa treatment group.

[0132] As Figure 6 shows, after 14 days of negative pressure treatment, the senescent cells (β-gal positive, blue in the figure) in the liver, kidney, spleen, brain and lung of senescent mice decreased.

[0133] As Figure 7 shows, compared with normal senescent mice, the vacuolar degeneration of the liver tissue of senescent mice after negative pressure treatment decreased significantly, the renal tubular casts were clearer; the thickness of the red pulp of the spleen tissue decreased, and the diameter of the white pulp increased; the heterochromatin around the cell nucleus in the brain tissue decreased, and the volume of the cell nucleus decreased; the inflammatory cells around the alveoli in the lung tissue decreased, and the alveolar structure was clearer.

[0134] Example 4 Comparison of young mice before and after negative pressure treatment

[0135] 1. Experimental method

[0136] Eight-week-old C57BL6 mice were used as test animals.

[0137] After the test animals were anesthetized, the hair on their backs was shaved off and treated with depilatory cream to remove the back hair.

[0138] Then, negative pressure treatment was applied to the test animals. The experimental groups included a control group (without negative pressure treatment), a local negative pressure group (treated with a local negative pressure of -0.02 MPa for 10 minutes per day for 7 days), a whole-body negative pressure -0.02 MPa treatment group (using the negative pressure chamber of the present disclosure, treated with a whole-body negative pressure of -0.02 MPa for 2 hours per day for 7 days), and a whole-body negative pressure -0.05 MPa treatment group (using the negative pressure chamber of the present disclosure, treated with a whole-body negative pressure of -0.05 MPa for 2 hours per day for 7 days).

[0139] From day 0 to day 7, the hair growth was observed by taking pictures every day. After 7 days of negative pressure treatment, the animals were returned to the normal breeding environment for 7 days, and then on day 14, pictures were taken to observe hair growth and the animals were anesthetized for blood collection for routine blood tests.

[0140] 2. Experimental results

[0141] (1) Effect of negative pressure treatment on hair regeneration in mice

[0142] Figure 8 Shows the hair growth of young mice in the control group, local negative pressure group, whole-body negative pressure -0.02 MPa treatment group, and whole-body negative pressure -0.05 MPa treatment group every day from day 0 to day 7 and on day 14. Figure 9 Shows the skin condition of the local negative pressure group before and after local negative pressure (local negative pressure -0.05 MPa, time 10 min).

[0143] As Figure 8 shown, compared with the control group, the local negative pressure -0.02 MPa treatment group had no obvious effect on promoting hair regeneration; in the whole-body negative pressure -0.02 MPa treatment group on day 14, compared with the local negative pressure -0.02 MPa treatment group, it showed an obvious effect on promoting hair regeneration; while in the whole-body negative pressure -0.05 MPa treatment group, based on the effect achieved by the whole-body negative pressure -0.02 MPa treatment group, its effect on promoting hair regeneration was further significantly improved.

[0144] The effect of whole-body negative pressure cannot be achieved by local negative pressure. This is not only because, as mentioned above, through mechanism exploration, the applicant found that the systemic mechanism changes brought about by whole-body negative pressure are not possessed by local negative pressure, for example, their effects on the body's circulatory system are significantly different. Moreover, whole-body negative pressure can achieve some situations that local negative pressure cannot implement. For example, through experiments, local negative pressure is not applicable to larger negative pressure conditions such as -0.05 MPa that can achieve better effects in whole-body negative pressure. As Figure 9As shown, when attempting to apply the same pressure under local negative pressure conditions, i.e., local negative pressure of -0.05 MPa, it causes obvious mechanical damage to the mouse skin.

[0145] Figure 10A Figure shows the comparison chart of white blood cell content of young mice in the control group, local negative pressure group, whole-body negative pressure -0.02 MPa treatment group, and whole-body negative pressure -0.05 MPa treatment group on the 14th day. As Figure 10A shown, on the 14th day (7 days after recovery from 7 days of negative pressure treatment), the blood routine results show that the proportion of white blood cells in the local negative pressure group increases significantly, further confirming that local negative pressure may cause an inflammatory response in the body.

[0146] (2)Changes in blood routine of young mice before and after negative pressure

[0147] Figure 10A Figure –10D shows the comparison chart of blood routine values of young mice in the control group, local negative pressure group, whole-body negative pressure -0.02 MPa treatment group, and whole-body negative pressure -0.05 MPa treatment group on the 14th day, where Figure 10A is the white blood cell content, Figure 10B is the red blood cell content, Figure 10C is the platelet content, Figure 10D is the lymphocyte proportion.

[0148] As Figure 10A Figure –10D shows that after whole-body negative pressure in young mice, the white blood cells decrease and the lymphocyte proportion increases. Compared with whole-body negative pressure, the proportions of white blood cells and red blood cells in the local negative pressure group increase significantly, and the platelets increase.

[0149] Example 5 Changes in human blood oxygen concentration in a negative pressure chamber

[0150] Generate negative pressures of various negative pressure values in the negative pressure chamber ( Figure 11 A), and use a blood oxygen detector to detect the blood oxygen concentration of the subjects under various negative pressure values. As Figure 11 shown, within the range of 0 MPa to -0.06 MPa, there is no obvious change in the blood oxygen concentration of humans ( Figure 11 B).

[0151] Example 6 Removal of senescent cells by negative pressure

[0152] As Figure 12 ( Figure 12 A- Figure 12As shown in (D), the P2 bone marrow mesenchymal stem cells (BMMSCs) of senescent mice, the P25 umbilical cord mesenchymal stem cells (UMSCs) induced to senescence by artificial continuous passage, and young cells were placed in an incubator with normal oxygen and negative pressure. After treatment with -0.05 Mpa for a period of time, they were taken out and fixed, and then stained with β-galactosidase to observe senescent cells. It was found that compared with young BMSCs / UMSCs, the number of β-Gal positive (blue) cells in senescent BMSCs / UMSCs gradually decreased under negative pressure treatment, while there was no obvious change in young BMSCs / UMSCs.

[0153] Example 7 Negative pressure treatment for osteoporosis in senescent mice

[0154] 1. Experimental method

[0155] Eighteen-month-old C57BL6 mice were used as test animals. The experimental groups included young mice and a control group (senescent mice without negative pressure treatment) (using the negative pressure chamber disclosed in the present application, the whole body was treated with negative pressure of -0.05 MPa for 2 hours every day for 6 weeks). After negative pressure treatment, the mice were anesthetized and sacrificed, and peripheral blood mononuclear cells were isolated for β-Gal staining and P16 immunofluorescence staining. The femurs were scanned and analyzed using Scanco μCT50 (Scanco Medical AG, Switzerland).

[0156] 2. Experimental results

[0157] As Figure 13 ( Figure 13 A-13K) shown, negative pressure treatment can reduce the ratio of β-Gal and P16 positive cells in PBMCs, restore the osteoporosis phenotype of senescent mice, and improve various bone indexes.

[0158] Example 8 C. elegans experiment

[0159] 1. Experimental method

[0160] (1) C. elegans Life span experiment

[0161] Synchronized L4-stage N2 C. elegans were transferred to fresh NGM plates containing OP50, and 50 μM of 5-fluoro-2'-deoxyuridine was added to prevent offspring growth. According to the experimental design, the plates were placed in a negative pressure chamber every day for negative pressure treatment at different pressures for 1 h, and the number of surviving C. elegans was monitored and recorded. Every 48 h, they were picked onto new fresh NGM plates containing OP50 and continued to be observed and counted. When the C. elegans did not respond to repeated probing with a platinum wire, they were considered dead.

[0162] (2) Oil Red O staining

[0163] Transfer the synchronized N2 nematodes to a fresh NGM plate containing OP50, and place them in a negative pressure chamber according to the experimental design for negative pressure treatment at different pressures for 6 days, 1 hour per day. After washing the nematodes twice with M9 solution, collect the nematodes in each group and fix them in 60% isopropanol for 30 minutes. After centrifugation, add 60% Oil Red O staining solution to each sample and incubate overnight at room temperature. After staining, wash the samples twice with M9 solution and observe the lipid droplets using an inverted microscope.

[0164] (3)Quantitative detection of triglycerides

[0165] Transfer the synchronized N2 nematodes to a fresh NGM plate containing OP50, and place them in a negative pressure chamber according to the experimental design for negative pressure treatment at different pressures for 6 days, 1 hour per day. After washing the nematodes twice with M9 solution, collect the nematodes in each group in RIPA lysis buffer and perform tissue homogenization. After collecting the lysate, centrifuge at 12,000 rpm for 30 minutes, collect the supernatant, and measure the protein concentration by BCA assay. According to the instructions of the triglyceride test kit (Nanjing Jiancheng), use an enzyme-linked immunosorbent assay (ELISA) reader to quantitatively detect the triglyceride content in each group of samples, and perform normalization uniformly as the final result (triglyceride content divided by protein content).

[0166] (4)Acute heat stress experiment

[0167] Transfer the synchronized N2 nematodes to a fresh NGM plate containing OP50, and place them in a negative pressure chamber according to the experimental design for negative pressure treatment at different pressures for 6 days, 1 hour per day. Randomly select 20 nematodes from each group onto a fresh NGM plate, transfer them to an incubator at 37 °C for 4 hours, and place them at room temperature for 12 hours after the heat treatment. Observe and count the survival rate of the nematodes.

[0168] 2. Experimental results

[0169] (1)Changes in the lifespan of nematodes before and after negative pressure

[0170] Nematodes exposed to pressures of -0.03 Mpa to -0.05 Mpa can extend their lifespan. Under the condition of -0.05 Mpa, the maximum lifespan is extended by 26.31%. ( Figure 14 ). Compared with the control group, the locomotor ability of the senescent nematodes (11 days) after negative pressure treatment is better ( Figure 15 ).

[0171] (2)Changes in the stored fat content of nematodes before and after negative pressure

[0172] After negative pressure treatment, nematodes reduce the deposition of lipid droplets in their bodies. Under the condition of -0.05 Mpa, negative pressure also significantly reduces the triglyceride content of nematodes ( Figure 16 ). The results suggest that negative pressure treatment enhances the hydrolysis of lipids in nematodes and reduces the stored fat in nematodes.

[0173] (3) Changes in the heat stress resistance ability of nematodes before and after negative pressure

[0174] Compared with the control group, nematodes after negative pressure treatment could maintain a higher survival rate under acute heat stress ( Figure 17 ), and the nematodes in the -0.05 Mpa negative pressure group had the best resistance to acute heat stress. The results suggest that negative pressure treatment improves the heat tolerance of nematodes and has a protective effect on nematodes under acute heat stress.

[0175] Example 9 Negative pressure treatment of non-alcoholic steatohepatitis (NASH)

[0176] 1. Experimental method

[0177] Mice with non-alcoholic steatohepatitis induced by a high-fat diet for 22 weeks were treated with negative pressure for 14 days, -0.05 Mpa per day for 2 hours. After 14 days, they were anesthetized with isoflurane, and blood was collected for routine blood tests after anesthesia. After blood collection, they were sacrificed by cervical dislocation, and then various tissue organs such as the heart, liver, spleen, lung, and kidney were separated. After fixation with paraformaldehyde, dehydration, paraffin embedding and other treatments were carried out, and then tissue sections with a thickness of 5 μm were cut. HE staining, oil red staining and Sirius red staining were performed on the liver for observation. At the same time, serum ALT and serum / tissue cholesterol contents were detected.

[0178] 2. Experimental results

[0179] HE staining of tissue sections showed that the fatty vacuolar degeneration was significantly reduced after negative pressure, the liver tissue was arranged in an orderly manner, and the infiltration of inflammatory cells was significantly reduced ( Figure 18 ). Oil red staining showed that the fatty vacuoles were significantly reduced after negative pressure, and the oil red staining in the negative pressure group was reduced ( Figure 19 ). Sirius red staining showed a slight improvement in liver fibrosis ( Figure 20 ). NAS score showed a significant improvement in non-alcoholic fatty liver ( Figure 21 ). Serum ALT detection showed that ALT in the negative pressure group was significantly reduced and there was no statistical difference from the healthy group ( Figure 22 ). The plasma and tissue cholesterol contents were both reduced, with statistical differences ( Figure 23 ).

[0180] Example 10 Negative pressure treatment of periodontitis in mice

[0181] 1. Experimental method

[0182] After 2 months of modeling chronic periodontitis (CP), the silk thread was removed. In the experimental group (CP + negative pressure), negative pressure (-0.05 Mpa) was applied for 2 hours every day. After 1 month, the mice were anesthetized and sacrificed, and the jawbones were isolated. Scanco μCT50 (Scanco Medical AG, Switzerland) was used to scan and analyze the changes in alveolar bone.

[0183] 2. Experimental results

[0184] Compared with the control group (CP group), the bone defect area in the negative pressure group was significantly reduced (P>0.05) ( Figure 24 ).

[0185] Example 11 Negative pressure treatment of hyperuricemia in mice

[0186] 1. Experimental method

[0187] The mice were gavaged by the combined method of potassium oxonate + hypoxanthine, once a day for 14 consecutive days to establish a chronic hyperuricemia mouse model.

[0188] Experimental grouping: ① Negative control group (Ctrl); ② Hyperuricemia mouse model group (UA); ③ Hyperuricemia mice + negative pressure treatment group (UA+NP). The hyperuricemia mice were treated with negative pressure (-0.05 Mpa) for 2 hours every day and given diet induction at the same time. After 14 days of negative pressure treatment, the activities of mice in each group were observed. After anesthesia, blood was collected for routine blood tests, and mouse neutrophil isolation solution was used to isolate mouse neutrophils for flow cytometry apoptosis. After blood collection, the mice were sacrificed by cervical dislocation, and then tissues and organs such as the liver and kidneys were isolated. After fixation with paraformaldehyde, dehydration, paraffin embedding, cryosectioning, etc. were carried out, and then tissue sections with a thickness of 5 μm were cut. HE staining, Masson staining, immunofluorescence, etc. were used to observe tissue changes. The negative pressure treatment procedure was the same as before.

[0189] 2. Experimental results

[0190] Compared with the mice in the negative control group, the percentage of lymphocytes in the hyperuricemia mouse group decreased, and the percentage of neutrophils increased. Negative pressure treatment could up-regulate the proportion of lymphocytes and down-regulate the proportion of neutrophils in the blood of hyperuricemia mice. In addition, the hyperuricemia model had little effect on the various data of red blood cells in the blood. Moreover, compared with the mice in the negative control group, the number of platelets in the hyperuricemia mouse group increased, and negative pressure treatment could significantly reduce the number of platelets in the hyperuricemia mouse group ( Figure 25 A- Figure 25 C).

[0191] Compared with the mice in the negative control group, the body weight of the hyperuricemia mice group decreased and their activity weakened. Negative pressure treatment could improve the body weight of hyperuricemia mice ( Figure 26 ). In addition, the activity of hyperuricemia mice weakened, and negative pressure could improve the activity of hyperuricemia mice ( Figure 27 ).

[0192] Compared with the mice in the negative control group, the blood uric acid of the hyperuricemia mice group increased. Negative pressure treatment could reduce the concentration of blood uric acid in mice; urea nitrogen BUN (a protein metabolite, representing renal function), negative pressure treatment could reduce the BUN content in the blood of hyperuricemia mice; serum creatinine CRE is a muscle metabolite, an indicator of renal function, and negative pressure could reduce the CRE content in the blood of hyperuricemia mice; xanthine oxidase XOD represents liver function, and negative pressure could reduce the enzyme activity of XOD in the blood of hyperuricemia mice ( Figure 28 ).

[0193] Compared with the mice in the negative control group, the liver of hyperuricemia mice showed hepatocyte vacuolar degeneration and an increase in abnormal nuclei, and negative pressure treatment could significantly improve the histological changes in the liver of hyperuricemia mice. Compared with the mice in the negative control group, the kidney tissue of hyperuricemia mice showed glomerular atrophy and disordered renal tubular structure, and negative pressure treatment could significantly improve the histological changes in the kidneys of hyperuricemia mice ( Figure 29 ). Masson staining further verified this result ( Figure 30 ). Compared with the mice in the negative control group, the kidney tissue of hyperuricemia mice showed obvious neutrophil inflammatory death, namely NETosis. Negative pressure treatment could significantly reduce the neutrophil inflammatory death in the kidneys of hyperuricemia mice ( Figure 31 ).

[0194] Example 12 Negative pressure relieves mouse depression / anxiety

[0195] 1. Experimental method

[0196] C57BL / 6 mice in the normal control group and 10 - 12-week-old LPR test mice (Fas-deficient apoptotic gene mice) before negative pressure treatment were subjected to anxiety / depression behavioral tests through open field tests, elevated plus maze tests, and forced swimming tests. Mice in the negative pressure (-0.05 Mpa) treatment group were treated with negative pressure for 2 h every day. After 14 days of treatment, they were subjected to open field tests, elevated plus maze tests, and forced swimming tests together with C57BL / 6 mice in the normal control group and LPR mice without negative pressure treatment to detect behavioral changes. The data were analyzed and processed using Jiliang behavioral analysis software.

[0197] 2. Experimental results

[0198] The performance of mice in the open field test and the elevated plus maze test can be used to evaluate the anxiety level of mice, while the cumulative time of immobility in the forced swimming test reflects the degree of depression in mice. Compared with the control group, the whole-body -0.05 Mpa negative pressure treatment group can significantly increase the distance traveled by LPR mice in the central area of the open field ( Figure 32 ). At the same time, compared with the pre-treatment movement of the mice themselves, the LPR mice in the whole-body -0.05 Mpa negative pressure treatment group can significantly increase the distance traveled in the central area of the open field before their own treatment ( Figure 32 ). In addition, the whole-body -0.05 Mpa negative pressure treatment group can significantly increase the movement time and entry times of LPR mice on the open arms of the elevated plus maze ( Figure 33 ). At the same time, compared with the pre-treatment movement of the mice themselves, the whole-body -0.05 Mpa negative pressure treatment group can significantly increase the movement time and entry times on the open arms of the elevated plus maze before their own treatment ( Figure 34 - 35 ). In the forced swimming test, the immobility time of the mice in the whole-body -0.05 Mpa negative pressure treatment group was significantly shorter than that of the untreated LPR mice ( Figure 36 ). The above experimental data confirm that the anxiety / depression level of mice is reduced after negative pressure treatment.

[0199] Example 13 Negative pressure treatment of murine enteritis

[0200] 1. Experimental method

[0201] After subjecting 8-week-old C57BL6 test mice to negative pressure treatment for 3 days, a 3% (w / v) DSS aqueous solution was added to the drinking water to construct a murine colitis model. Among them, the mice in the enteritis + negative pressure group were treated with negative pressure (-0.05 Mpa) for 2 h every day, and the mice in the enteritis group and the control group served as the positive control and the negative control respectively. The DSS solution was changed every two days. After 10 days of modeling, the mice in each group were anesthetized and sacrificed, and the colon samples were harvested and the colon length from the cecum to the rectum was measured to evaluate the severity of colitis.

[0202] 2. Experimental results

[0203] Compared with the control group mice, DSS treatment reduced the colon length, but after negative pressure treatment, the colon length of the mice showed an increasing trend, indicating that negative pressure treatment weakened the colitis caused by DSS ( Figure 37 ).

[0204] Example 14 Negative pressure treatment of murine Alzheimer's disease (AD)

[0205] 1. Experimental method

[0206] Six 7-month-old APP / PS1 mice were randomly and evenly divided into two groups: the AD negative pressure group and the AD control group. The AD negative pressure group was treated with whole-body negative pressure of -0.05 Mpa for 2 h every day; the AD control group was not treated. Another six 7-month-old wild-type C57BL6 mice were randomly and evenly divided into two groups: the WT negative pressure group and the WT control group. The WT negative pressure group was treated with whole-body negative pressure of -0.05 Mpa for 2 h every day; the WT control group was not treated. After two weeks of treatment for all the above mice, Morris water maze tests were conducted to analyze the escape time of each group of mice, and statistical analysis was performed to judge the learning and memory abilities of the mice.

[0207] 2. Experimental results

[0208] As Figure 38 shown, after two weeks of -0.05 Mpa negative pressure treatment, the escape time of APP / PS1 mice in the Morris water maze decreased significantly, approaching that of wild-type mice, indicating that the learning and memory abilities of APP / PS1 mice were significantly restored.

[0209] Example 15 Negative pressure treatment for atherosclerosis

[0210] 1. Experimental method

[0211] Atherosclerosis transgenic model mice, ApoE- / - mice, were treated with negative pressure (-0.05 Mpa) for 2 h every day. After continuous treatment for 2 months, they were anesthetized and sacrificed. The aortic arch of the mice was isolated and cut open, and after fixation, oil red O staining was performed.

[0212] 2. Experimental results

[0213] The results were as Figure 39 shown in A-39C. In the negative pressure group (Exp), the formation of atherosclerotic plaques decreased, and triglyceride (TG) and total cholesterol (T-CHO) in the blood decreased.

[0214] The foregoing has outlined the features of several embodiments or examples so that those skilled in the art may better understand the various aspects of the present disclosure. Those skilled in the art should understand that they can readily use the present disclosure as a basis for designing or modifying other processes and structures for performing the same purposes and / or achieving the same advantages as the embodiments or examples described herein. Those skilled in the art should also realize that such equivalent structures do not depart from the spirit and scope of the present disclosure, and various changes, substitutions, and alterations can be made to this document without departing from the spirit and scope of the present disclosure.

Claims

1. A negative pressure chamber for providing negative pressure to an individual, characterized in that, Comprising: A cabin body that can accommodate the entire body of the individual; A negative pressure device provided on the cabin body; An oxygen supply device provided on the cabin body or inside the cabin of the cabin body; And An oxygen supply apparatus connected to the oxygen supply device and communicating with the air pressure inside the cabin of the cabin body through the oxygen supply device; An oxygen supply port connected to the oxygen supply device.

2. The negative pressure chamber for providing negative pressure to an individual according to claim 1, wherein The oxygen supply apparatus is used to supply oxygen to the oxygen supply device.

3. The negative pressure chamber for providing negative pressure to an individual according to claim 1, characterized in that, The length of the cabin body is at least 1 meter.

4. The negative pressure chamber for providing negative pressure to an individual as claimed in claim 1, wherein, The length of the cabin body is 1 to 2 meters.

5. The negative pressure chamber for providing negative pressure to an individual according to claim 1, characterized in that, The length of the cabin body is 1 to 1.5 meters.

6. The negative pressure chamber for providing negative pressure to an individual according to claim 1, characterized in that, It further includes a negative pressure breaking device provided on the cabin body. In the first state of the negative pressure breaking device, the inside and outside of the cabin are airtight, and in the second state of the negative pressure breaking device, the inside and outside of the cabin are air-connected.

7. The negative pressure chamber for providing negative pressure to an individual according to claim 1, characterized in that, It further includes a perspective structure provided on the cabin body to make the inside of the cabin visible relative to the outside of the cabin, and / or make the outside of the cabin visible relative to the inside of the cabin.

8. The negative pressure chamber for providing negative pressure to an individual according to any one of claims 1-7, characterized in that, At least a part of the oxygen supply device is located inside the cabin.

9. The negative pressure chamber for providing negative pressure to an individual according to any one of claims 1-7, characterized in that, The oxygen supply port is an oxygen mask and / or an oxygen inhalation tube.

10. The negative pressure chamber for providing negative pressure to an individual according to any one of claims 1-7, characterized in that, It further includes: A display device provided on the cabin body; A lighting device provided on the cabin body and facing the inside of the cabin; And / or A control device provided on the cabin body to control at least one of the negative pressure device and the oxygen supply device.

Images